Clinical and Economic Implications of AF Related Stroke
- PMID: 27909470
- PMCID: PMC5089483
- DOI: 10.4022/jafib.1279
Clinical and Economic Implications of AF Related Stroke
Abstract
A major cause of morbidity and mortality among patients with atrial fibrillation (AF) relates to the increased risk of stroke. The burden of illness that AF imparts on stroke is likely to increase with our aging populations and increasingly sophisticated cardiac monitoring techniques. Understanding the clinical and economic differences between AF related ischaemic stroke and non-AF related stroke is important if we are to improve future cost effectiveness analyses of potential preventative treatments, but also to help educate clinical and policy decision makers on use or availability of treatments to prevent AF related stroke. In this article we review the existing evidence that highlights differences in the clinical characteristics and outcomes between AF and non-AF stroke, as well as differences in their economic impact and discuss ways to improve future economic analyses.
Keywords: Atrial Fibrillation; Cost Effectiveness; Costs; Stroke Outcomes.
Similar articles
-
Cost of acute stroke care for patients with atrial fibrillation compared with those in sinus rhythm.Pharmacoeconomics. 2015 May;33(5):511-20. doi: 10.1007/s40273-015-0263-1. Pharmacoeconomics. 2015. PMID: 25693879
-
The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation.J Atr Fibrillation. 2011 Feb 22;3(5):340. doi: 10.4022/jafib.340. eCollection 2011 Feb-Apr. J Atr Fibrillation. 2011. PMID: 28496686 Free PMC article.
-
Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands.Europace. 2018 Jan 1;20(1):12-18. doi: 10.1093/europace/euw285. Europace. 2018. PMID: 27733465
-
Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation.Vascul Pharmacol. 2016 Aug;83:26-35. doi: 10.1016/j.vph.2016.03.006. Epub 2016 May 16. Vascul Pharmacol. 2016. PMID: 27196706 Review.
-
Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.Ann Pharmacother. 2013 May;47(5):671-85. doi: 10.1345/aph.1R411. Epub 2013 Apr 19. Ann Pharmacother. 2013. PMID: 23606551 Review.
Cited by
-
A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.Pharmacoeconomics. 2019 Jul;37(7):895-919. doi: 10.1007/s40273-019-00795-4. Pharmacoeconomics. 2019. PMID: 30949988
-
Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries.J Clin Med. 2025 May 7;14(9):3252. doi: 10.3390/jcm14093252. J Clin Med. 2025. PMID: 40364283 Free PMC article.
-
Hybrid Decision Support to Monitor Atrial Fibrillation for Stroke Prevention.Int J Environ Res Public Health. 2021 Jan 19;18(2):813. doi: 10.3390/ijerph18020813. Int J Environ Res Public Health. 2021. PMID: 33477887 Free PMC article.
-
Anticoagulant use in older persons at risk for falls: therapeutic dilemmas-a clinical review.Eur Geriatr Med. 2023 Aug;14(4):683-696. doi: 10.1007/s41999-023-00811-z. Epub 2023 Jul 1. Eur Geriatr Med. 2023. PMID: 37392359 Free PMC article. Review.
-
Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study.PLoS Med. 2024 Aug 29;21(8):e1004377. doi: 10.1371/journal.pmed.1004377. eCollection 2024 Aug. PLoS Med. 2024. PMID: 39207948 Free PMC article.
References
-
- Miyasaka Yoko, Barnes Marion E, Gersh Bernard J, Cha Stephen S, Bailey Kent R, Abhayaratna Walter P, Seward James B, Tsang Teresa S M. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114 (2):119–25. - PubMed
-
- Go A S, Hylek E M, Phillips K A, Chang Y, Henault L E, Selby J V, Singer D E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285 (18):2370–5. - PubMed
-
- Schnabel Renate B, Yin Xiaoyan, Gona Philimon, Larson Martin G, Beiser Alexa S, McManus David D, Newton-Cheh Christopher, Lubitz Steven A, Magnani Jared W, Ellinor Patrick T, Seshadri Sudha, Wolf Philip A, Vasan Ramachandran S, Benjamin Emelia J, Levy Daniel. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015 Jul 11;386 (9989):154–62. - PMC - PubMed
-
- Patel Nileshkumar J, Deshmukh Abhishek, Pant Sadip, Singh Vikas, Patel Nilay, Arora Shilpkumar, Shah Neeraj, Chothani Ankit, Savani Ghanshyambhai T, Mehta Kathan, Parikh Valay, Rathod Ankit, Badheka Apurva O, Lafferty James, Kowalski Marcin, Mehta Jawahar L, Mitrani Raul D, Viles-Gonzalez Juan F, Paydak Hakan. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014 Jun 10;129 (23):2371–9. - PubMed
-
- Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22 (8):983–8. - PubMed
Publication types
LinkOut - more resources
Full Text Sources